December 16, 2025 · Economy, Trade & Fiscal Policy
· market reaction
Developing
Trump Confirms Marijuana Reclassification Plan, Cannabis Stocks Slide on Profit-Taking
In mid-December 2025, Trump confirmed he was strongly considering an executive order to reclassify marijuana from a Schedule I to a Schedule III drug under the Controlled Substances Act, a move he signed on December 18. The order also proposed a pilot program letting Medicare cover certain cannabis products for seniors. Rather than rallying further, cannabis-linked stocks, which had surged in the days before on anticipation of the announcement, gave back gains as investors took profits once the news was confirmed.
The reaction reflected market skepticism about the pace and durability of federal drug-policy shifts. Rescheduling marijuana has been proposed and studied for years without full implementation, and investors have grown wary of distinguishing rhetorical momentum from enacted policy.
Politically, the announcement let the administration claim action on a long-debated drug-policy issue popular with voters across the spectrum. Substantively, the reclassification still requires implementation by the Attorney General and faces regulatory and legal steps before it takes full effect, leaving the market's initial enthusiasm tempered by uncertainty over timeline and scope.
The reaction reflected market skepticism about the pace and durability of federal drug-policy shifts. Rescheduling marijuana has been proposed and studied for years without full implementation, and investors have grown wary of distinguishing rhetorical momentum from enacted policy.
Politically, the announcement let the administration claim action on a long-debated drug-policy issue popular with voters across the spectrum. Substantively, the reclassification still requires implementation by the Attorney General and faces regulatory and legal steps before it takes full effect, leaving the market's initial enthusiasm tempered by uncertainty over timeline and scope.